AGREEMENT AND PLAN OF MERGER among: BESPIN SUBSIDIARY, LLC, BESPIN MERGER SUB, INC., LANDOS BIOPHARMA, INC., and ABBVIE INC., solely for the limited purposes set forth herein. Dated as of March 24, 2024Agreement and Plan of Merger • March 25th, 2024 • Landos Biopharma, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 25th, 2024 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER is made and entered into as of March 24, 2024, by and among: Bespin Subsidiary, LLC, a Delaware limited liability company and a wholly owned Subsidiary of Guarantor (“Parent”); Bespin Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub”); Landos Biopharma, Inc., a Delaware corporation (the “Company”); and solely for the purposes of Section 2.2(b)(iii), Section 2.3(b), Section 5.1(b), Section 5.5, Section 5.10, Section 5.11, Section 8.4, Section 8.5, Section 8.7 and Section 8.10, AbbVie Inc., a Delaware corporation (“Guarantor”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER DATED AS OF JUNE 11, 2023, AMONG NOVARTIS AG, CHERRY MERGER SUB INC. AND CHINOOK THERAPEUTICS, INC.Agreement and Plan of Merger • June 12th, 2023 • Chinook Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledJune 12th, 2023 Company Industry JurisdictionThis AGREEMENT AND PLAN OF MERGER, dated as of June 11, 2023 (this “Agreement” and, such date, the “Agreement Date”), by and among Novartis AG, a company organized under the laws of Switzerland (“Parent”), Cherry Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent (“Merger Sub”), and Chinook Therapeutics, Inc., a Delaware corporation (the “Company”). Unless expressly stated otherwise, Parent, Merger Sub and the Company are referred to in this Agreement individually as a “party” and collectively as the “parties”.